Clinical trial
The Safety and Efficacy of 5-HT3 Receptor Antagonist (Ramosetron) Versus Psyllium (Agio®) for the Treatment of Fecal Incontinence: Multicenter Randomized Trial (SERAFI)
NCT06166615 is registered in ClinicalTrials.gov with Seoul National University Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Safety and Efficacy of 5-HT3 Receptor Antagonist (Ramosetron) Versus Psyllium (Agio®) for the Treatment of Fecal Incontinence: Multicenter Randomized Trial (SERAFI)
- Lead sponsor
- Seoul National University Hospital
- Phase
- Phase 2/3
- Overall status
- Unknown status
- Start date
- December 15, 2023
- Completion date
- November 1, 2024
- Enrollment
- 148 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.